Evidence map›Paper›PMID 35022405›Full record

ArticleCell death discovery2022

CircRNA circTIAM1 promotes papillary thyroid cancer progression through the miR-646/HNRNPA1 signaling pathway.

Deguang Zhang, Li Tao, Nizheng Xu, Xiaoxiao Lu, Jianle Wang, Gaofei He, Qinghu Tang, Kangmao Huang, Shuying Shen, Junjie Chu

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Current issues in molecular biology · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Deguang Zhang *Department of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China.ORCID http://orcid.org/0000-0001-6854-9655
Li Tao *Department of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China.
Nizheng Xu *Department of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China.
Xiaoxiao LuDepartment of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China.
Jianle WangDepartment of orthopaedic surgery, Sir Run Run Shaw Hospital, Zhejiang University school of Medicine & Key laboratory of Musculoskeletal system Degeneration and regeneration Translational research of Zhejiang Province, 3 east Qingchun road, Hangzhou, 310016, People's Republic of China.
Gaofei HeDepartment of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China.
Qinghu TangDepartment of general surgery, People's Hospital of Linghu, Nanxun District, Huzhou, Zhejiang Province, People's Republic of China.
Kangmao HuangDepartment of orthopaedic surgery, Sir Run Run Shaw Hospital, Zhejiang University school of Medicine & Key laboratory of Musculoskeletal system Degeneration and regeneration Translational research of Zhejiang Province, 3 east Qingchun road, Hangzhou, 310016, People's Republic of China.
Shuying ShenDepartment of orthopaedic surgery, Sir Run Run Shaw Hospital, Zhejiang University school of Medicine & Key laboratory of Musculoskeletal system Degeneration and regeneration Translational research of Zhejiang Province, 3 east Qingchun road, Hangzhou, 310016, People's Republic of China. 11207057@zju.edu.cn.ORCID http://orcid.org/0000-0002-4523-8501
Junjie ChuDepartment of head and neck surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, People's Republic of China. 3316033@zju.edu.cn.ORCID http://orcid.org/0000-0003-3289-5657
Sir Run Run Shaw Hospital · CNThe People's Hospital of LinXia · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary thyroid cancer (PTC) is a common endocrine tumor with a rapidly increasing incidence in recent years. Although the majority of PTCs are relatively indolent and have a good prognosis, a certain proportion is highly aggressive with lymphatic metastasis, iodine resistance, and easy recurrence. Circular RNAs (circRNAs) are a class of noncoding RNAs that are linked to a variety of tumor processes in several cancers, including PTC. In the current study, circRNA high-throughput sequencing was performed to identify alterations in circRNA expression levels in PTC tissues. circTIAM1 was then selected because of its increased expression in PTC and association with apoptosis, proliferation, and migration of PTC cells in vitro and in vivo. Mechanistically, circTIAM1 acted as a sponge of microRNA-646 and functioned in PTC by targeting miR-646 and heterogeneous ribonucleoprotein A1. Fluorescence in situ hybridization and dual-luciferase reporter assays further confirmed these connections. Overall, our results reveal an important oncogenic role of circTIAM1 in PTC and may represent a potentially therapeutic target against PTC progression.

Identifiers

PMID35022405
PMCPMC8755710
OpenAlexW4206519081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.